U.S. Personal Products Stock News

Century Aluminum recently reported fourth-quarter 2025 results, with revenue of US$633.7 million and net income of US$1.8 million, and its CEO Jesse Gary has since presented the company’s outlook and operational plans at the BMO Global Metals, Mining & Critical Minerals Conference in Florida. Alongside these earnings, Century Aluminum is pushing ahead with an expansion of U.S. production and a new Oklahoma smelter project, signaling a major bet on reshoring and tariff-supported domestic...

Earlier this week, Bruker Corporation unveiled major upgrades across its spatial biology and proteomics portfolio, including the PaintScape 3D genome visualization platform, the CellScape XR spatial proteomics system, Functional Proteomics 2.0 workflows on timsOmni, and a new Spatial Biology Center of Excellence with the University of Glasgow. Together, these launches and collaborations deepen Bruker’s presence in high-content multiomics and translational research tools, potentially...

In February 2026, Belden Inc. reported past fourth-quarter 2025 sales of US$720.12 million and net income of US$67.89 million, alongside full-year 2025 sales of US$2.72 billion and net income of US$237.52 million, while outlining first-quarter 2026 guidance and confirming continued share repurchases. The combination of higher earnings, ongoing buybacks totaling US$154.91 million for 1.35 million shares, and an active M&A agenda underlines Belden’s focus on long-term value creation. With...

Why CMS Energy (CMS) is on investors’ radar today CMS Energy (CMS) has not been driven by a single headline event recently, but its recent share performance and fundamentals give investors several concrete data points to weigh. The stock’s recent returns span a mixed short term picture and a stronger longer term track record. CMS is up 0.6% over the past day, has slipped about 0.6% over the past week, and is higher by 7.9% over the past month. Looking further out, the total return stands at...

Rollins, Inc. recently reported higher fourth-quarter and full-year 2025 earnings, continued to signal a healthy M&A pipeline, and earlier this month presented its outlook at Barclays’ 43rd Annual Industrial Select Conference in Miami. Management’s emphasis on recurring revenue, disciplined acquisitions, and confidence in funding further deals after investing almost US$900 million over three years highlights how central M&A has become to Rollins’ growth ambitions. We’ll now examine how...

Plexus overview after recent trading move Plexus (PLXS) has drawn fresh attention after a recent move in its share price, with the stock last closing at $197.55. That level reflects a 1 day return of about a 0.5% decline and a 7 day return of roughly a 1.9% decline. See our latest analysis for Plexus. While Plexus has seen a modest 1 day share price pullback and a softer 7 day share price return, the 30 day share price return of 13.52% and 90 day share price return of 38.52% sit alongside a 1...

Neurocrine Biosciences (NBIX) is back in focus after reporting fourth quarter and full year 2025 earnings, alongside fresh 2026 sales guidance for INGREZZA and optimistic commentary around its late stage pipeline. See our latest analysis for Neurocrine Biosciences. At a latest share price of US$128.38, Neurocrine Biosciences has seen short term share price pressure, with a 30 day share price return of a 5.73% decline and a 90 day share price return of a 10.56% decline. However, a 1 year total...

Why ICU Medical is back on investors’ radar ICU Medical (ICUI) has moved back into focus after resolving a longstanding FDA warning letter tied to its Smiths Medical business and posting fourth quarter results with adjusted earnings above analyst expectations, along with 2026 guidance that came in ahead of consensus. The company paired these updates with detailed 2026 earnings guidance, giving investors clearer visibility into expected GAAP net income of US$26 million to US$44 million and...

On 17 February 2026, Bernstein Litowitz Berger & Grossmann LLP filed a class action alleging that Express Scripts, Cigna, and Evernorth diverted billions in drug rebates to a Swiss affiliate, Ascent, using disguised “fees” and formulary decisions that allegedly favored higher-paying drug manufacturers over lower-cost alternatives. The lawsuit directly challenges how Express Scripts and its parent Cigna structure and disclose PBM rebate economics, raising complex questions about fiduciary...

Trinity Industries (TRN) is back in focus after its latest quarterly results and 2026 earnings outlook, which highlighted higher net income and earnings per share along with lower sales compared with the prior year. See our latest analysis for Trinity Industries. At a share price of $34.60, Trinity Industries has given investors a 28.0% 1 month share price return and 31.2% 3 month share price return. Its 1 year total shareholder return of 19.4% points to momentum that has been building rather...

Americold Realty Trust, Inc. reported fourth-quarter 2025 results showing sales of US$600.68 million and revenue of US$658.45 million, with net loss widening to US$88.34 million and loss per share from continuing operations at US$0.31. Alongside these weaker results, the company introduced a new Chief Financial Officer, Chris Papa, and set out a detailed 2026 plan focused on balance sheet repair, cost reductions, and targeted growth in higher-value cold storage segments. Next, we’ll examine...

Ultra Clean Holdings, Inc. reported fourth-quarter 2025 revenue of US$506.6 million, down from US$563.3 million a year earlier, and moved from net income of US$16.3 million to a net loss of US$3.3 million, contributing to a full-year 2025 loss of US$181.2 million on slightly lower annual revenue of US$2.05 billion. Despite the swing to losses, the company guided first-quarter 2026 revenue to US$505 million–US$545 million and GAAP diluted EPS between a loss of US$0.13 and earnings of US$0.03,...

Gentherm (THRM) is back in focus after reporting fourth quarter and full year 2025 results that showed much lower net income alongside record revenue, along with new revenue guidance for 2026 and 2027. See our latest analysis for Gentherm. The latest results and 2026 to 2027 revenue guidance came as the share price closed at $32.51, with a 1 day share price return of 4.69% decline and a 1 year total shareholder return of 4.35% decline. This points to pressure on the Gentherm story after...

UGI stock reacts to Q1 earnings and business reshaping UGI (UGI) is in focus after Q1 FY 2026 earnings, a major business reshaping in Europe, senior leadership changes, and expansion into new U.S. states drew fresh attention to the stock. See our latest analysis for UGI. At a share price of US$37.45, UGI has seen a 1 day share price return of 2.19% decline and a softer 7 day and 30 day share price return. However, its 1 year total shareholder return of 17.38% and 5 year total shareholder...

Stoke Therapeutics recently reported that it has dosed the first patient in its Phase 1 OSPREY trial of STK-002, an investigational antisense oligonucleotide designed to boost OPA1 protein expression and potentially treat Autosomal Dominant Optic Atrophy, a rare inherited cause of progressive, irreversible vision loss with no approved therapies. This first-in-human study moves Stoke’s TANGO platform into a new ophthalmic indication, offering an early real-world test of whether upregulating...

In February 2026, Amgen Inc. issued and sold US$4.00 billion of fixed-rate senior unsecured notes maturing between 2031 and 2056, with coupons ranging from 4.200% to 5.650% and net proceeds of about US$3.96 billion to support its corporate financing needs. This large, multi-tranche bond deal, alongside the recent European Commission approval of UPLIZNA for generalized myasthenia gravis, highlights how Amgen is pairing balance-sheet funding with expansion of its rare autoimmune...

Bunge Global recently reported past quarterly results showing revenue growth of very large year on year, beating analyst expectations while also completing the transformational Viterra combination and advancing major growth projects. Despite missing full-year EPS guidance and gross margin estimates, the company’s integration of Viterra and focus on renewable feedstocks and plant-based ingredients appear central to its evolving business mix. Next, we’ll examine how this strong revenue...

Graham Holdings (GHC) has been drawing attention after recent share price moves, including a 1 day decline and mixed returns over the past month and past 3 months. These developments are prompting investors to reassess this diversified holding company. See our latest analysis for Graham Holdings. At a share price of US$1,069.64, Graham Holdings has seen pressure in the short term, with a 30 day share price return of an 8.74% decline. Longer term performance, reflected in an 18.24% 1 year...

If you are wondering whether Global Payments is starting to look like value, you are not alone. The stock has attracted fresh attention from investors asking if the current price still reflects its long term potential. After a strong 7 day return of 16.1% to US$79.49, recent performance over 30 days at 5.7% and year to date at 5.2% sits against a much softer picture over longer periods, with 1 year, 3 year and 5 year returns of 22.5%, 27.9% and 58.9% declines respectively. Recent headlines...

Faruqi & Faruqi, LLP has begun investigating McKesson’s Board over potential fiduciary breaches tied to the 2013 Stock Plan and its recommendation to issue 30,000,000 additional shares, raising concerns about the impact on existing shareholders. This scrutiny focuses attention on how governance decisions around equity issuance could affect ownership stakes and the company’s long-term capital allocation approach. We’ll now examine how concerns about substantial share issuance and potential...

What recent performance says about Alexandria Real Estate Equities Alexandria Real Estate Equities (ARE) has drawn fresh attention after a mixed stretch in the stock, with a small gain over the past week, a decline over the past month, and a modest rise across the past 3 months. See our latest analysis for Alexandria Real Estate Equities. That recent mix of short term gains and a softer 30 day share price return of 9.95% sits against a year to date share price return of 9.76%. At the same...

If you are wondering whether SBA Communications is attractively priced or still looks expensive at around US$199.64, starting with a clear view of its valuation can help you frame the opportunity and the risks. The stock has been relatively flat over the last week with a 0.6% decline, while the 30 day return sits at 6.7% and the 1 year return at a 4.3% decline. Some investors may see this as a reset after a 19.0% decline over 3 years and a 13.6% decline over 5 years. Recent coverage has...

Genesis Energy, L.P. recently expanded its previously announced cash tender offer for 7.750% senior notes due 2028, moving from a US$490 million cap to an “any and all” structure, funded by new senior unsecured notes due 2034 and other fixed-income financing completed in February 2026. This combination of a broadened bond buyback and fresh longer-dated debt issuance highlights an assertive approach to reshaping Genesis Energy’s capital structure and managing upcoming maturities. We’ll now...

Apple (AAPL) is back in focus after record fiscal Q1 2026 results, strong iPhone demand, and growing services revenue, paired with fresh AI product plans and moves to reshore parts of its supply chain. See our latest analysis for Apple. Apple’s recent AI announcements, reshoring efforts and record Q1 results appear to have supported a 7.31% 1 month share price return, even though the year to date share price return is slightly negative and the 5 year total shareholder return of 113.86% points...